早产儿视网膜病变抗VEGF治疗后复发相关因素
回顾性分析43例80眼1型ROP或更严重患儿,接受0.25 mg贝伐珠单抗或雷珠单抗玻璃体腔注射,14眼(17.5%)复发,IVB组13.5%、IVR组20.9%(P=0.556);多因素分析显示治疗时矫正胎龄≤35周(P=0.014)和侵袭性后部ROP(P=0.044)与复发显著相关;IVR后血清VEGF第1天和第7天显著抑制,第14天恢复至注射前水平。
要点
- 抗VEGF治疗可降低所有患眼ROP活动性,但17.5%患眼复发。
- 治疗时矫正胎龄≤35周和侵袭性后部ROP与复发显著相关。
- IVB与IVR复发率差异无统计学意义(13.5% vs 20.9%,P=0.556)。
核心结论
- IVR和IVB均能有效降低ROP活动性,但抗VEGF治疗后复发可能与治疗时较小矫正胎龄和侵袭性后部ROP相关。
研究设计与样本
- 回顾性研究纳入2012年1月至2018年2月连续43例80眼1型ROP或更严重患儿,IVB组37眼接受0.25 mg贝伐珠单抗,IVR组43眼接受0.25 mg雷珠单抗,并检测18例患者IVR前后血清VEGF浓度。
主要发现
- 抗VEGF注射治疗降低所有眼ROP活动性,但14眼(17.5%)出现复发。
- IVB组和IVR组复发率分别为13.5%和20.9%(P=0.556)。
- 多因素logistic回归显示抗VEGF治疗时矫正胎龄≤35周(P=0.014)和侵袭性后部ROP(P=0.044)与复发显著相关。
- IVR后血清VEGF在第1天(P<0.001)和第7天(P=0.012)显著抑制,第14天恢复至注射前水平(P=0.210)。
临床怎么用
- 对接受抗VEGF治疗的ROP患儿,应关注治疗时矫正胎龄≤35周和侵袭性后部ROP等复发高危因素。
- IVR后血清VEGF抑制短暂,第14天恢复至基线,提示需密切随访ROP复发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the efficacy and risk factors of intravitreal antivascular endothelial growth factor injection (anti-VEGF therapy) for retinopathy of prematurity (ROP). METHODS: We retrospectively reviewed 80 consecutive eyes of 43 patients with Type 1 ROP or worse who received anti-VEGF therapy during January 2012-February 2018. Patients were divided into those who were injected with 0.25 mg of bevacizumab (IVB group, 37 eyes) and 0.25 mg of ranibizumab (IVR group, 43 eyes). Serum VEGF concentrations of 18 patients were measured before and after IVR. RESULTS: Antivascular endothelial growth factor injection therapy reduced ROP activity in all eyes; however, 14 eyes (17.5%) exhibited reactivation. The reactivation rates of the IVB and IVR groups were 13.5% and 20.9%, respectively (P = 0.556). Multivariate logistic regression analysis showed that postmenstrual age ≤35 weeks at anti-VEGF therapy (P = 0.014) and aggressive posterior ROP (P = 0.044) was significantly associated with reactivation. Serum VEGF was significantly suppressed at Days 1 (P < 0.001) and 7 (P = 0.012) after IVR and returned to the preinjection level by Day 14 (P = 0.210). CONCLUSION: Both IVR and IVB seemed effective in reducing ROP activity. Reactivation after anti-VEGF therapy may be associated with younger postmenstrual age at anti-VEGF therapy and aggressive posterior ROP.
引用
- Iwahashi C, Utamura S, Kuniyoshi K, et al. FACTORS ASSOCIATED WITH REACTIVATION AFTER INTRAVITREAL BEVACIZUMAB OR RANIBIZUMAB THERAPY IN INFANTS WITH RETINOPATHY OF PREMATURITY. Retina. 2021. PMID: 33958533. doi:10.1097/IAE.0000000000003196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。